Compliance filter
FDA-Inspected biotech companies in Europe — compliance directory
FDA inspection means the US Food and Drug Administration has audited a manufacturing or testing facility against US regulations — typically GMP for drugs (21 CFR 210/211), Quality System Regulation for devices (21 CFR 820), or GLP for nonclinical (21 CFR 58). For European facilities, an FDA inspection record signals that the site can supply the US market under existing approvals or has demonstrated US-grade compliance during a regulatory review. This page lists European biotech, pharma, and CDMO facilities with publicly documented FDA inspection markers — a non-trivial filter for diligence buyers, US-bound supply chain teams, and licensors.
Where is this standard strongest?
Not yet available.. Top cities: Not yet available.. Most visible records: Not yet available..
Which categories carry this standard?
Not yet available.. Latest review: Pending. Review cycle: June 2026.
Why this standard matters
This page helps separate vague claims from records where the quality or regulatory marker is already visible in public evidence.
Related market brief
How biologics manufacturing, drug discovery, and pharmaceutical logistics connect across Germany, Poland, and the Baltics — with named companies and routes you can actually use.
Open related briefFull list
FDA-Inspected records
0 compliance records currently match the active filter.
No records match the current filter set.
No matching record found
We could not find a public record that matches the current filter set. Try a broader search or submit a company for review.
No records in this layer match the current filter.
FAQ
Frequently asked questions
- What does FDA-Inspected mean?
- It means the US FDA has conducted at least one inspection of the facility — pre-approval, surveillance, or for-cause. The outcome categories are: NAI (No Action Indicated), VAI (Voluntary Action Indicated), or OAI (Official Action Indicated). FDA inspection records are tracked publicly via the FDA Inspections Database and 483/Warning Letter releases. A clean inspection record is a strong external signal of regulatory readiness for US-bound product.
- Which European countries have the most FDA-inspected biotech facilities?
- Switzerland and Germany dominate — pharma majors (Roche, Novartis, BioNTech, Bayer) maintain dense FDA inspection records across multiple sites. Denmark (Novo Nordisk, Lundbeck) and Sweden (AstraZeneca) carry significant FDA-inspected manufacturing. Lithuania (Northway/Biotechpharma) and Poland (Polpharma) have FDA-inspected CDMO and finished-dose facilities. Smaller markets typically rely on a single FDA-inspected site for US-bound supply.
- Why does FDA inspection matter for European companies?
- For European pharma and CDMO operators selling into the US, FDA inspection is the practical gate to commercial supply. Without a passed FDA inspection, a foreign facility cannot be cleared for US drug import under most pathways. For diligence buyers, an FDA-inspected European site signals (a) the operator already meets a higher external quality bar than EU GMP alone, and (b) the facility can be relied on for US-bound contracts without re-qualification overhead.
- How are FDA-inspected companies verified in this directory?
- Every profile is hand-reviewed: the FDA-Inspected marker requires evidence from a primary source — an FDA Inspections Database record, an FDA-issued 483 or NAI/VAI/OAI letter, an FDA-published warning or compliance action notice, or operator documentation referencing a specific FDA inspection. Self-claimed FDA inspection without traceable documentation does not earn the marker.
Next step
Read the compliance filter, then move into cities and categories.
This page works best as a starting filter. For deeper comparison, use city, category, and methodology pages.